Literature DB >> 24512738

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

Petra Votavova1, Jakub Tomala1, Marek Kovar2.   

Abstract

IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (γ(c) chain) and CD122 (β chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor α chains CD25 and IL-15Rα, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Rα is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 mAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122(high) populations (memory CD8(+) T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only CD25(high) cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Rα-Fc chimera; however, IL-15/IL-15Rα-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/IL-15Rα-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-IL-2 mAb; Biological activity; IL-15; IL-15Rα-Fc chimera; IL-2; Immunocomplexes

Mesh:

Substances:

Year:  2014        PMID: 24512738     DOI: 10.1016/j.imlet.2014.01.017

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

1.  Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Nat Rev Rheumatol       Date:  2016-09-02       Impact factor: 20.543

2.  Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.

Authors:  Lauryn E Klevorn; Melissa M Berrien-Elliott; Jinyun Yuan; Lindsey M Kuehm; Gregory D Felock; Sean A Crowe; Ryan M Teague
Journal:  Cancer Immunol Res       Date:  2016-11-01       Impact factor: 11.151

3.  Immune responses of bison and efficacy after booster vaccination with Brucella abortus strain RB51.

Authors:  S C Olsen; J L McGill; R E Sacco; S G Hennager
Journal:  Clin Vaccine Immunol       Date:  2015-02-11

4.  Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.

Authors:  Marie T Kim; Martin J Richer; Brett P Gross; Lyse A Norian; Vladimir P Badovinac; John T Harty
Journal:  J Immunol       Date:  2015-09-25       Impact factor: 5.422

5.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

6.  Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.

Authors:  Kristina S Burrack; Matthew A Huggins; Emily Taras; Philip Dougherty; Christine M Henzler; Rendong Yang; Sarah Alter; Emily K Jeng; Hing C Wong; Martin Felices; Frank Cichocki; Jeffrey S Miller; Geoffrey T Hart; Aaron J Johnson; Stephen C Jameson; Sara E Hamilton
Journal:  Immunity       Date:  2018-04-03       Impact factor: 43.474

7.  A Mouse Model of Latent Tuberculosis Infection to Study Intervention Strategies to Prevent Reactivation.

Authors:  Andreas Kupz; Ulrike Zedler; Manuela Stäber; Stefan H E Kaufmann
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies.

Authors:  Boris Shulgin; Gabriel Helmlinger; Yuri Kosinsky
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  Bacterial Manipulation of NK Cell Regulatory Activity Increases Susceptibility to Listeria monocytogenes Infection.

Authors:  Sarah E Clark; Holly C Filak; Brandon S Guthrie; Rebecca L Schmidt; Amanda Jamieson; Patricia Merkel; Vijaya Knight; Caroline M Cole; David H Raulet; Laurel L Lenz
Journal:  PLoS Pathog       Date:  2016-06-13       Impact factor: 6.823

10.  Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Authors:  Frida Ewald Sander; Malin Nilsson; Anna Rydström; Johan Aurelius; Rebecca E Riise; Charlotta Movitz; Elin Bernson; Roberta Kiffin; Anders Ståhlberg; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén; Anna Martner
Journal:  Cancer Immunol Immunother       Date:  2017-07-18       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.